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Abstract
Background—The Human papillomavirus (HPV) vaccine has been available for protection 
against HPV-associated cervical cancer and genital warts since 2006. Nonetheless, uptake has 
varied among countries and populations within countries. Studies have found that individuals’ 
knowledge and attitudes toward the vaccine are associated with immunization uptake. The purpose 
of the current review is to summarize and evaluate the evidence for educational interventions to 
increase HPV vaccination acceptance.
Methods—We searched the databases of PubMed and Web of Science for English-language 
articles describing educational interventions designed to improve HPV vaccination uptake, 
intention or attitude.
Results—We identified 33 studies of HPV vaccination educational interventions: 7 tested the 
effectiveness of interventions with parents, 8 with adolescents or young adults, and 18 compared 
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the effectiveness of different message frames in an educational intervention among adolescents, 
young adults or their parents. Most studies involved populations with higher educational 
attainment and most interventions required participants to be literate. The minority of studies used 
the outcome of HPV vaccine uptake. Well-designed studies adequately powered to detect change 
in vaccine uptake were rare and generally did not demonstrate effectiveness of the tested 
intervention.
Conclusions—There is not strong evidence to recommend any specific educational intervention 
for wide-spread implementation. Future studies are required to determine the effectiveness of 
culturally-competent interventions reaching diverse populations.
Keywords
Papillomavirus vaccines; Decision making; Intervention studies; Education; Attitude to health; 
Systematic review
1. Background
Human papillomavirus (HPV) is among the most common sexually transmitted infections 
with a global prevalence of 11–12% among women and with rates as high as 16–24% in 
some regions including sub-Saharan Africa, Eastern Europe and Latin America [1]. It is also 
the causative agent of nearly all cervical cancer, the second most common cancer in women 
worldwide [2]. Currently, there are two HPV vaccines that confer protection against HPV-
associated cervical cancer, as well as other anogenital cancers. The bivalent Cervarix® 
vaccine protects against HPV types 16 and 18 which cause roughly 70% of all cervical 
cancer [3]. The quadrivalent vaccine, Gardasil® protects against types 16 and 18 as well as 
types 6 and 11 which cause more than 90% of genital warts in men and women [4]. In 2006 
the U.S. was the first country to approve the quadrivalent vaccine for females, extending this 
approval to use in males in 2009. The bivalent vaccine was approved for females in the U.S. 
in 2009 and was licensed in other countries in Europe as well as Australia and the 
Philippines prior to 2009 [5]. Both vaccines are recommended for use as a 3-dose series over 
6 months before the onset of sexual activity and typically starting between ages 10 to 13 
years [6,7].
According to the World Health Organization’s monitoring system, HPV vaccine had been 
introduced in 57 countries by 2013 [8]. Overall, countries that have school-based 
vaccination programs, such as Australia, Great Britain and Portugal, have achieved the 
highest (80% or greater) female vaccination coverage rates [9], though Denmark has reached 
very high vaccination rates (3-dose coverage of over 80%) through administration by 
general practitioners [10]. Studies conducted in countries with national HPV immunization 
programs have demonstrated clear benefits of mass vaccination in terms of reductions in 
viral prevalence and associated disease burden. For instance, a recently published study 
from Australia found lower rates of high-grade cervical abnormalities and high-grade 
cytology among vaccinated women versus unvaccinated women (hazard ratio 0.72; 95% 
confidence interval (CI) = 0.58–0.91) [11]. Further Australian data, collected during the first 
5 years of their national immunization program, found that the incidence of genital warts 
decreased more than 50% among females under 30 and more than 70% in heterosexual 
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males of the same age [12]. Similarly, incidence data from Denmark shows that genital 
warts have declined an average of 3.1% every year since 2007 [10]. In the US, vaccine-type 
HPV prevalence decreased over 50% among females ages 14–19 years in the first 4 years 
post-licensure [13]. The vaccine is also safe; there have been no post-marketing surveillance 
reports of severe side effects [8,14–17].
Despite an excellent safety and efficacy profile, HPV vaccine uptake has varied between 
countries and between populations within countries. This is the case in Europe as well as 
among low and middle income countries that have universal vaccination programs [7]. 
Among high income countries with low coverage rates are France (28.5% for the full 3-dose 
series) and the United States. (34% for full coverage) [7,16]. A recent systematic review of 
studies mostly conducted in the U.S. examining correlates of HPV vaccine uptake in teenage 
girls identified the following personal cognitive factors: having higher vaccine-related 
knowledge, having a healthcare provider as a source of information and maintaining positive 
vaccine attitudes [9]. Therefore, interventions that improve understanding of, and positive 
attitudes toward HPV vaccine may increase HPV vaccination coverage. Previous successful 
behavioral interventions to increase compliance with other preventive health 
recommendations such as increasing sun protection behavior [18], improving dental hygiene 
[19], and increasing adherence to cervical and breast cancer screenings [20], for example, 
have employed various education delivery methods, including classroom lectures for 
adolescents [18], brief online education for parents [19], and home visits for women [20]. In 
our present systematic review, we focus on published evaluations of educational 
interventions designed to increase HPV vaccine acceptance in patients eligible to receive the 
vaccine, or their parents.”
2. Methods
2.1. Search strategies
We searched both the PubMed and Web of Science databases to ensure comprehensive 
capture of both the medical and social sciences literature (Web of Science having greater 
coverage of the social sciences than PubMed). We entered relevant MeSH (Medical Subject 
Headings) keywords (papillomavirus vaccines and decision making, behavioral research, 
intervention studies, communication, education or attitude to health) and limited the search 
by English language. Realizing that some studies were conducted prior to licensure of the 
HPV vaccine, we searched the maximum date coverage range available in PubMed at the 
time the search was conducted. Abstracts of all articles with a publication date between 1946 
to August 20, 2013 were reviewed for relevance to the study topic. Full-text articles were 
obtained for studies pertaining to the evaluation of educational interventions to increase 
HPV vaccination attitudes, intentions or uptake. Two authors independently reviewed the 
articles to determine relevance for inclusion. In addition, the references of retrieved papers 
and a recent systematic review of parental vaccine hesitancy interventions [21,22] were 
searched for studies that might have been missed in the original search strategy.
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2.2. Inclusion and exclusion criteria
We included trials that employed both randomized and nonrandomized designs, as well as 
quasi-experimental designs (i.e., comparing pre- and post-intervention outcomes). 
Educational interventions designed to improve patient or parental knowledge or attitudes, 
and which measured the following outcomes were included: (1) receipt of HPV vaccine (any 
dose or completion of the 3-dose series), (2) intention to receive HPV vaccine, or (3) attitude 
toward HPV vaccine. Non-English articles and conference abstracts were excluded. In 
addition, pilot or descriptive projects which reported only qualitative or anecdotal results 
were also excluded. Finally, studies that did not focus primarily on populations eligible to 
receive HPV vaccine or their parents or that did not subset results in a way that we were able 
to extract information on these target groups were also excluded.
2.3. Data extraction
A form was created and used to extract data from all articles to ensure a standardized 
process was applied. The elements included in the data extraction form were adapted from 
the GRADEprofiler evidence profile tool for creating Cochrane Reviews Summary of 
Findings tables and assessing the quality of the evidence. All items captured are reflected in 
the data presented in Tables 1–5 [23]. Two reviewers independently extracted data from 
each article and forms were reviewed jointly afterward to achieve consensus.
2.4. Data analysis
Studied interventions were too heterogeneous to perform meta-analysis and outcomes were 
reported in many different ways. To standardize reported outcomes as much as possible and 
thereby enhance the reader’s ability to compare effects across studies, reviewers calculated 
the relative risk (RR) and 95% confidence interval (CI) whenever sufficient data were 
provided, and outcomes involved a comparison of event probabilities. When response 
categories for HPV acceptance survey items included undecided/no response and no, these 
two categories were combined into a single category for comparison to yes responses. 
Generated RR and 95%CI are reported for post-intervention responses in tables along with 
the authors’ stated results as they appeared in the original articles. Some studies reported 
multiple outcomes. In such cases, we reported them in the following hierarchy: receipt of 
HPV vaccine in preference to intention to receive HPV vaccine in preference to attitude 
toward HPV vaccine. Our preferences for this hierarchy of outcomes were based on our 
understanding that intention to vaccinate is an approximation of vaccination behavior, while 
positive attitude is generally considered a precursor to intention [24].
If studies reported both between- and within-group comparisons, we preferentially reported 
between-group comparisons. If studies reported participant intention to receive the HPV 
vaccine free of cost or for a fee, we reported the outcomes for the free-of-cost vaccine since 
this removed the confounding factor of financial barriers. If studies included subgroup 
analysis or interaction terms between the intervention and other variables, we preferentially 
reported outcomes for the overall groups and main effects of the intervention, respectively.
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Each article was evaluated for risk of bias based on the methods suggested by the Cochrane 
Collaboration [25] including: condition allocation strategy, concealment of condition 
assignment to participants, research staff blinding, and inclusion of intent to treat analysis. 
Because the Cochrane criteria support evaluation of clinical trials, we omitted two other 
appraisal categories as not applicable to this review: loss to follow up (since the vast 
majority of included studies were conducted in one sitting) and confounding (since there is 
no consensus regarding which participant factors and theoretical constructs are highly 
associated with vaccination behavior) [9]. Beyond the Cochrane criteria, we included four 
additional appraisal categories to meet the objectives of this review: adequate reporting of 
participant eligibility criteria (e.g., exclusion of participants with prior HPV vaccination), 
inclusion of a no-treatment or standard-treatment control condition, adequate reporting of 
interventional and outcome details for the primary research question, and outcome 
assessment at any point beyond immediately post-intervention. Appraisal of each category 
and of an overall risk of bias rating (low, medium or high) for each article was performed by 
two reviewers. Any discrepancy in risk-of-bias rating was discussed to achieve consensus.
3. Results
3.1. Study characteristics
Our search resulted in a total of 33 relevant articles included in this review (Fig. 1). Studies 
were classified into the following categories: parental education (7 studies), adolescent/
young adult education (8 studies) and comparative message persuasiveness (18 studies). If 
the primary aim of a study was to evaluate the impact of a single educational intervention, 
compare different delivery modes for the same educational content (e.g., video vs. written 
information) or the “dose response” (i.e., differential effect of increasing the quantity, length 
of exposure or extent of education) of two or more educational interventions, the study was 
categorized as either adolescent/young adult or parental education as appropriate. If the 
primary aim of a study was to determine the differential effect of two or more interventions 
with essentially the same educational content but varying message frames, tones or 
messengers, the study was considered to be in the realm of comparative message 
persuasiveness.
3.2. Critical appraisal
In terms of risk of bias, we judged seven studies to be of low risk, fifteen of medium risk 
and eleven of high risk (Table 1). While the majority of included studies were randomized 
trials, most did not specify whether group assignment was concealed to participants or study 
personnel and did not include a standard-treatment or no-treatment control group. Most 
studies did not evaluate interventions with the preferred outcome, HPV vaccination receipt, 
but rather a proxy of acceptance (intent or attitude). Over half (55%) of the studies did not 
adequately report interventional and outcome details for the primary research question. 
Specifically, these studies lacked sufficient descriptions of: their survey measurement 
scales’ items or scoring, the educational content of their interventions, the main effects or 
significance levels of their outcomes, and the numbers of participants allocated to initial 
treatment conditions and/or completing protocol.
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We identified seven articles that tested interventions to educate parents of minors in the 
recommended age range for HPV vaccination (Table 2). Of these, five were conducted in 
the United States [26–29] and other two were from India [30] and China [31]. Less than half 
the studies were randomized, controlled trials [27,28,32] with most designed as quasi-
experimental comparisons of parental intentions to vaccinate pre- versus post-intervention 
[26,29–31]. All but two of the studies [26,27] exclusively surveyed parents of girls and none 
of the studies involved any follow-up assessment beyond the period immediately following 
the intervention. All of the studies used the primary outcome of self-reported indicators of 
HPV vaccine acceptability rather than actual vaccination behavior (i.e., child’s HPV 
vaccination status post-intervention), although in the study by Spleen et al., the authors did 
assess self-reported HPV vaccination receipt one month post-intervention among nine, non-
randomly-selected participants [29]. It would not have been possible to assess actual 
vaccination receipt in four of the studies since they were conducted prior to HPV vaccine 
licensure in the study country [26,27,30,31].
The format for five of the parental educational interventions was written information fact 
sheets from 1 to 2 pages in length [26–28,30,31]. Although some of the studies provided 
more detailed descriptions of the content of the fact sheets given to participants, all provided 
information on aspects of the potential morbidity associated with HPV infection and 
informed parents of the current or future availability of an HPV vaccine to protect children 
against infection. Of the studies examining the effectiveness of parental information sheets, 
the two that were randomized, controlled trials [27,28] found no difference in HPV 
vaccination intention between the experimental and control conditions. The three studies 
that exclusively compared HPV vaccination intention pre- to post-intervention found a 
significant increase in intention to vaccinate in parents after they had read the information 
sheet with risk ratios (RR) and 95% confidence intervals (CI) ranging from 1.60 (1.23–2.08) 
to 2.88 (2.47–3.36) [26,30,31] while the study by Kennedy et al, which reported results both 
within-group as well as between-groups, did not (P = 0.74) [28].
Just two studies examined the effects of parental educational interventions that were not 
fact-sheet based. Spleen et al. tested the effectiveness of a 1-h slide presentation about HPV 
infection to parents of girls in Appalachian Pennsylvania. This study found increases in 
scores for intention to accept the HPV vaccine after the presentation of less than 1 point on a 
4 point-scale (P = 0.002) although it should be noted that 31% of the sampled parents had 
daughters who had already started the HPV vaccination series at the time of the intervention 
[29]. A study by Kepkaet al. [32] tested the effectiveness of a Spanish-language radio 
advertisement (referred to as radionovela in the study) to educate Latino parents about HPV 
vaccination. This study did not find any difference in intention to vaccinate one’s daughter’s 
between the experimental and control conditions, (RR = 0.86 (95%CI 0.65–1.13)), although 
it may have been under-powered as it enrolled only 60 participants.
3.4. Adolescent/young adult education
Our search strategy yielded eight educational studies which targeted adolescents or young 
adults (Table 3). Half of the studies targeted younger adolescents in secondary or high 
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school [33–36]. Participants’ ages, specified in all but one of these studies, ranged from 12 
to 16 years overall. The other half of the studies either partially [37] or exclusively recruited 
participants from colleges [33,36,38,39]. The age range of these participants ranged from 18 
to 26 years in the two studies in which age criteria were specified [37,39]. Three studies 
were conducted in the United States [37–39], two in England [33,36], and one study each in 
Sweden [34], Hong Kong [35] and Canada [40]. Half of the studies involved both male and 
female participants [34,36,38,40] and half were limited to females [33,35,37,39]. All but one 
of the studies [33] were conducted after the HPV vaccine was licensed in the country from 
which participants were recruited.
Formats for the educational interventions involving adolescent and young adult participants 
varied. The interventions tested in three of the studies were brief HPV educational videos 
ranging in length from 3 to 10 min [33,37,40]. Two studies tested hour-long, live 
presentations delivered at school [34,35]. Three studies tested written HPV fact sheets 
[36,39,40] and one an online fact sheet with a question-and-answer section and a self-quiz 
[38].
Of note, three studies were randomized controlled trials that used the preferred outcome of 
vaccination behavior [34,37,39]. The outcome of interest in two of the three studies was 
receipt of the first dose of HPV vaccine. The first of these studies was conducted by Patel, et 
al. and tracked HPV vaccine uptake via medical record review up to 6 months after the 
intervention [39]. For this intervention, college-aged women were given a written fact sheet, 
discussed the contents with the study coordinator and received a second copy in the mail two 
weeks later. The comparator group received a different HPV vaccination fact sheet (“with 
similar content”) once with no reminder mailing and no review of the content. Rate of 
receipt of the first dose of HPV vaccine in the intervention group was low (5.5%) and did 
not differ significantly from that of the control group. The other study was conducted by 
Gottvall et al. and tested the impact of an hour-long lesson on HPV and condom usage for 
high school students with handouts and online resources [34]. The comparator groups in this 
study did not receive any education on these topics. Rate of self-reported receipt of the first 
dose of HPV vaccine in the intervention group was also low (16%) and not significantly 
different from that of the control groups [34,39]. Vanderpool et al. conducted a trial 
comparing completion rates of the 3-dose HPV vaccination series among young women who 
received the first dose from study personnel [37]. In this study, the difference between the 
intervention and control conditions was viewing a 13-min video about HPV or not. Both 
conditions received a CDC-produced HPV vaccine fact sheet and a t-shirt. The authors 
report 11% more participants in the intervention versus control group received all 3 doses of 
HPV vaccine within 9 months as assessed via medical record review (RR = 1.36; 95%CI = 
1.03–1.79) [37].
The remaining studies of adolescent and young adult education assessed effects on 
behavioral intention or attitudes rather than actual vaccination behavior. Four of the five 
studies were randomized, controlled trials [33,36,38,40]. All five found significant 
improvement by their chosen measure as assessed immediately post-intervention. However, 
only one of these studies re-assessed outcome 1 month later, and it found no significant 
difference between intervention and control groups at follow up [38].
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3.5. Comparative message persuasiveness
We identified eighteen articles with interventions that tested how the framing of messages 
about the HPV vaccination influenced vaccine acceptance [41–58] (Table 4). Four of the 
studies recruited parents exclusively [41,44,46,55], thirteen recruited college aged-
participants [42,43,45,47–53,56–58], and one recruited a broad sample of adults from which 
we report the subgroup analysis involving parents with minor girls eligible to receive the 
HPV vaccine [54]. Three of the studies involving parent participants only included parents 
of girls [41,54,55] and two included parents of boys or girls [41,46]. Of the studies involving 
college-aged participants, seven included women only [43,45,48,49,51–53], three men only 
[42,47,50] and three included both men and women [56–58]. Overall, the age of participants 
(when reported) for college-based samples was 18–26 years old [42,43,51,52,56–58]. 
Thirteen of the studies were American [41,42,47–51,53–58], two were Canadian [45,46], 
two were Australian [43] and one was Irish [44]. All four studies with Gerend as the lead 
author as well as a fifth conducted by Leader, et al. were conducted prior to the licensure of 
the HPV vaccine for the study’s target population (namely males and females or males 
exclusively) [47–50,54]. The rest were conducted post-licensure [41–46,51–53,55–58]. 
Because the objective of all eighteen studies was to compare two or more framing messages, 
all included at least one comparison group although only four included a standard-treatment 
or no-treatment control condition [41,43,51,58]. All studies in this category assigned 
treatment condition randomly.
In terms of format, the majority of the interventions in this category were presented as 
written materials either as 1–2 page brochures and fact sheets [41,44,47–50,52,53,55] or as 
online content [45,46,54,56–58]. One intervention involved slide presentations [42], another 
radio advertisements [43], and a third videos [51].
Researchers took a variety of approaches to framing the HPV vaccination message including 
comparing: (1) gain—(advantages of getting vaccinated) versus loss—(disadvantages of not 
getting vaccinated) framed messages; (2) different delivery formats (e.g., narrative versus 
informative presentation styles, color priming with red versus gray, and graphic versus non-
graphic presentation of HPV infection risk statistics); and (3) different message content foci 
(cervical cancer versus genital warts prevention) (Table 5).
The most common message-framing model tested was gain versus loss framing with nine 
studies represented. None of these found any main effects of gain versus loss framing on 
HPV vaccination intention [44–46,55]. However, some studies did find that gain/loss 
framing affected HPV vaccination intention under particular circumstances (as demonstrated 
by significant interactions with other variables including aspects of sexual history [48]; 
number of vaccinations required for immunity [49]; among persons primed with red versus 
gray color [50]; among persons characterized as present-versus future-minded [57]; and 
among persons characterized as avoidance- versus approach-oriented [48,56]).
There were five studies that compared messages focusing on the different diseases prevented 
by HPV vaccination [42,50,52–54]. Although these studies were conducted with a variety of 
types of participants (parents, young men, and young women), none found a differential 
direct effect of their messages on HPV immunization intention [42,50,52,54]. However, one 
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study found that self-efficacy and response efficacy sequentially mediated the positive 
indirect influence of their genital warts prevention message (vs. a cervical cancer prevention 
message) on HPV vaccination intention among young women [53].
Sixteen studies in this category examined the effect of message framing on HPV vaccination 
intention only and none of these studies assessed outcomes beyond immediately post-
intervention [41–50,53–58]. We here highlight the two message framing trials that used the 
preferred outcome of interest, HPV vaccine uptake [51,52]. Both of these studies assessed 
vaccination receipt by participant self-report 2 months after the intervention. In a large study 
by Hopfer et al., female college students in the experimental condition viewed brief videos 
with a narrative message delivered by different source types: peers, medical experts and 
combined peers and medical experts [51]. Compared with the control group, only the 
combined peer-expert group reported statistically higher vaccination rates. The effect size 
was relatively large with participants in the combined peer-expert group twice as likely to 
report having been vaccinated. The other study to use self-reported HPV vaccination as the 
outcome of interest included a smaller sample. It involved 75 female college students with 
half reading a fact sheet explaining the benefits of HPV vaccine for cervical cancer 
prevention only and the other half reading a fact sheet explaining the benefits for prevention 
of cervical cancer and genital warts [52]. This study did not find a statistically significant 
difference between the two groups in immunization rates.
4. Discussion
We identified 33 studies of HPV vaccination educational interventions: 7 tested the 
effectiveness of interventions with parents, 8 with adolescents or young adults and 18 
compared the effectiveness of different message frames. Unfortunately, our review did not 
identify any clearly superior interventions meriting strong recommendation for wide-spread 
implementation. Well-designed studies adequately powered to detect change in vaccine 
uptake were rare and generally did not demonstrate effectiveness of the tested intervention.
In comparing the outcomes of the randomized trials of educational interventions for 
adolescents and young adults versus parents, it seems that adolescents’ and young adults’ 
intention to receive HPV vaccination may be more readily influenced by educational 
interventions. In fact, all five of the adolescent/young adult education studies examining 
effect on vaccination intention or attitude found significant improvement as assessed 
immediately post-intervention regardless of the format and content of the education. This is 
in contrast to none of the three randomized trials targeting parents. Perhaps the difference is 
due in part to the study setting: most of the studies involving adolescents and young adults 
occurred at school or university where students may have been already primed for learning. 
Nonetheless, even among adolescents and young adults, there is no evidence that the 
positive intentions and attitudes achieved by HPV educational interventions are durable or 
that they impact vaccine uptake. In the only adolescent/young adult education study to 
include a follow-up assessment, higher intention to be vaccinated seen immediately post-
intervention was extinguished after 1 month [38]. Furthermore, the two educational trials 
involving adolescents/young adults that used receipt of the first dose of HPV vaccine as the 
primary outcome found no significant increase in uptake as a result of their interventions 
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[34,39]. Since virtually all of the interventions were completed in a single session with 
minimal or no reinforcement at a later time, it is possible that the positive effect of a single-
episode educational intervention on HPV vaccination intention may not be robust enough to 
affect vaccination behavior among adolescents and young adults who have yet to receive the 
first dose. On the other hand, enhanced single-session education may increase compliance 
with completion of the 3-dose series among participants who are given the first dose at the 
time of the education as demonstrated by Vanderpool et al. [37]. This is worth noting for 
further exploration since rates of completion of the series understandably lag behind rates of 
series initiation [7,16].
Two recent reviews have included HPV immunization educational interventions in their 
searches: one focused on parental acceptance of childhood vaccines [22], and the other 
included any intervention to increase HPV acceptance [5]. These two reviews include 9 [22] 
and 7 [5] articles relevant to HPV vaccination education, respectively. The findings of these 
other reviews are similar to our own in that many of the identified studies were 
methodologically deficient and results were difficult to generalize [5,22].
The most common message-framing dichotomy tested in studies we identified as part of this 
review was gain- versus loss-framing. None of the nine studies showed significant main 
effects of gain-/loss-framing. Our negative findings are consistent with a recent meta-
analysis which found no significant difference between gain and loss frame messages in 
persuading people to be vaccinated [59]. Taken together, we can surmise that the 
relationship between gain-/loss-message frame and HPV vaccine acceptance, if it exists at 
all, is complex and only relevant under particular circumstances and when moderated by 
other factors.
Another common framing theme among the identified studies was varying the specifics of 
HPV disease prevention messages provided to participants, most often between cervical 
cancer and genital warts prevention messages. Since none of these studies found any 
difference in vaccination intention between treatment conditions, it is possible that HPV 
vaccination educational interventions need not focus on one particular aspect of disease 
prevention to be effective.
One of the major challenges we found with the studies included in this review was the 
limited generalizability of their findings. Despite the fact that cervical cancer mortality 
disproportionately affects socioeconomically disadvantaged populations [60], only thirteen 
(39%) of the studies in this review included populations outside the university setting. Of 
these, only six tested an intervention that did not require participants to be literate [29,32–
35,37]. Only one study tested a culturally-tailored intervention in a population at risk for 
under-immunization (specifically Hispanic Americans), and this study was likely under-
powered [32]. Since many of the studies were conducted pre-licensure or in the early years 
of the HPV vaccine usage in the study country, it was reasonable and appropriate at that 
time to test educational interventions among anyone eligible to receive or consent for 
vaccination. However, at this juncture, new research should shift focus to populations at 
higher risk of disease or under-vaccination.
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One limitation of our review is that our search was restricted to English-language 
publications. Therefore, the results are difficult to generalize beyond Western European, 
Australian and North American populations. Furthermore, the vast majority of reviewed 
studies comparing different message frames for HPV vaccination education were conducted 
in the U.S. (72%). Given that social norms and beliefs differ by culture, care must be 
exercised when extrapolating the findings of this review to other populations.
Comparing the studies identified in this review and their conclusions highlighted the 
potential for bias in different approaches for testing educational interventions. For instance, 
all four of the parental educational studies that compared within-group attitudes or intentions 
(from pre- to post-intervention) found a significant improvement [26,29–31]. However, none 
the three that utilized a randomized controlled design found improvement between groups 
[27,28,32]. When restricted to analyzing within-group data alone, there is no way to 
determine whether improvement in participant HPV vaccination acceptance may have been 
partly due to unintended learning about the vaccination from a detailed survey, or to social 
desirability bias because participants gained a sense of the study’s aims. This increases the 
chances of researchers making the type I error of incorrectly concluding that improvements 
were the result of the intervention and underscores the importance of the randomized, 
controlled design for future studies.
5. Conclusion
Given the association between HPV vaccination acceptance and individual knowledge, 
attitudes and beliefs, finding effective HPV vaccination educational interventions is essential 
to reducing HPV-associated morbidity and mortality [9,61–63]. Studies to date have largely 
focused on written informational handouts targeted toward educated populations. Future 
studies should focus on culturally-competent interventions to reach a more diverse 
population. Trials should be adequately powered, employ strong research methodology and 
examine HPV vaccine uptake as the primary outcome.
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Table 1
Quality appraisal of included studies.
Total studies (33) Yes N (%) No N (%) Unclear N (%) N/A N (%)
Were eligibility criteria adequately reported (inclusion and exclusion)? 28 (85) 5 (15) 0 0
Were there two or more comparative groups? 28 (85) 5 (15) 0 0
 Was group assignment random? 25 (76) 1 (3) 2 (6) 5 (15)
 Was group assignment concealed to participants? 9 (27) 1 (3) 18 (55) 5 (15)
 Was study staff blinded to group assignment? 4 (12) 0 24 (73) 5 (15)
 Was a no-treatment or standard-treatment control group included? 10 (30) 18 (55) 0 5 (15)
Was the outcome assessed actual receipt of HPV vaccine? 5 (15) 28 (85) 0 0
Were interventional and outcome details for the primary research question 
adequately reported?
15 (45) 18 (55) 0 0
Were outcomes assessed at any time beyond immediately post-intervention? 6 (18) 27 (82) 0 0
Was intent to treat analysis completed?a 0 8 (24) 1 (3) 24 (72)










For studies in which assessment required mailed responses or follow up.
b
Risk for all studies was classified as indicated by consensus rating of the quality of the evidence in the above-listed domains; only randomized, 
controlled trials could be classified as low risk of bias.
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